ArticleJournal of medicinal chemistry2020
Ultrapotent Inhibitor of
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 35 citations in OpenAlex.
- Incorporation of the Trifluoromethylthio Group (CFThe Journal of organic chemistry · 2026Review
- Carbadox, a veterinary growth promoter exhibits anticlostridial activity through induction of oxidative stress in Clostridioides difficile.Gut pathogens · 2026Article
- Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors withJournal of medicinal chemistry · 2026Article
- Ionomycin Exhibits Potent and Selective Bactericidal Activity Against Clostridioides difficile Through Calcium-Dependent Membrane Disruption.MicrobiologyOpen · 2026Article
- Identification of the cannabinoid receptor 1 antagonist, ibipinabant, as a potent inhibitor ofAntimicrobial agents and chemotherapy · 2026Article
- Evaluation of the antibacterial activity of the natural product α-mangostin against Clostridioides difficile.PloS one · 2026Article
- Halogenated N-(1,3,4-oxadiazol-2-yl) benzamides are effective eradicators of methicillin-resistant Staphylococcus aureus biofilms.Bioorganic & medicinal chemistry · 2026Article
- Mechanistic Insights Into the Inhibition ofScientifica · 2026Article
- Hit-to-Lead Optimization of Acetazolamide-Based Bacterial Carbonic Anhydrase Inhibitors with Efficacy In Vivo for Treatment of Vancomycin-Resistant Enterococci Septicemia.Journal of medicinal chemistry · 2025Article
- Article
- Optimization of Ethoxzolamide Analogs with Improved Pharmacokinetic Properties forJournal of medicinal chemistry · 2024Article
- Article
- The state of play of rodent models for the study ofJournal of medical microbiology · 2024Review
- Molecular docking, dynamics andBioinformation · 2024Article
- Article
- Improved Antibacterial Activity of 1,3,4-Oxadiazole-Based Compounds That RestrictACS infectious diseases · 2023Article
- Substituted salicylic acid analogs offer improved potency against multidrug-resistant Neisseria gonorrhoeae and good selectivity against commensal vaginal bacteria.Scientific reports · 2023Article
- Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid asMolecules (Basel, Switzerland) · 2023Article
- Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively InhibitsJournal of medicinal chemistry · 2023Article
- Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment ofJournal of enzyme inhibition and medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.